Benjamin L. Palleiko
2019
In 2019, Benjamin L. Palleiko earned a total compensation of $2.1M as Chief Business Officer and Chief Financial Officer at Carbylan Therapeutics, a 155% increase compared to previous year.
Compensation breakdown
| Bonus | $192,150 |
|---|---|
| Option Awards | $994,555 |
| Salary | $366,000 |
| Stock Awards | $527,794 |
| Other | $11,000 |
| Total | $2,091,499 |
Palleiko received $994.6K in option awards, accounting for 48% of the total pay in 2019.
Palleiko also received $192.2K in bonus, $366K in salary, $527.8K in stock awards and $11K in other compensation.
Rankings
In 2019, Benjamin L. Palleiko's compensation ranked 5,698th out of 13,971 executives tracked by ExecPay. In other words, Palleiko earned more than 59.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,698 out of 13,971 | 59th |
Division Manufacturing | 2,132 out of 5,695 | 63rd |
Major group Chemicals And Allied Products | 766 out of 2,194 | 65th |
Industry group Drugs | 643 out of 1,880 | 66th |
Industry Pharmaceutical Preparations | 470 out of 1,392 | 66th |
Source: SEC filing on August 23, 2019.
Palleiko's colleagues
We found three more compensation records of executives who worked with Benjamin L. Palleiko at Carbylan Therapeutics in 2019.